About this market
Despite the significant research activities undertaken over the past several decades, a promising treatment with very few side effects is not yet developed for the treatment of epidermolysis bullosa. Hence, various government and private organizations are releasing funds to advance the research on the development of promising therapeutics that can demonstrate better safety and efficacy than the available medications for the treatment of epidermolysis bullosa. The funding for the research on epidermolysis bullosa in Europe is also increasing. Such funding and financial supports are helpful for the development of novel therapeutic drugs for the treatment of epidermolysis bullosa. analysts have predicted that the epidermolysis bullosa therapeutics market will register a CAGR of almost 5% by 2023.
Market Overview
Rising awareness about epidermolysis bullosa
Epidermolysis bullosa is a group of inherited diseases in which the skin becomes very brittle and forms acute blisters after a minor injury or gentle friction. Therefore, to avoid the delay in the diagnosis and the unawareness of the treatment options, several government and non-government organizations are conducting various awareness programs.
Lack of approved therapeutics
The unavailability of approved therapeutics for the treatment of epidermolysis bullosa is expected to hamper the growth of the epidermolysis bullosa therapeutics market over the forecast period.
For the detailed list of factors that will drive and challenge the growth of the epidermolysis bullosa therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.